Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333438 | 0.89 | PPARG (0.52) | PPARGPPARACTSSCTSKPDE2A | |
| SCHEMBL2833637 | 0.89 | PPARG (0.52) | PPARGPPARACTSSCTSKPDE2A | |
| SCHEMBL16633977 | 0.87 | PDE2A (0.51) | PPARGPPARACTSSCTSKPDE2A | |
| SCHEMBL27957364 | 0.82 | PPARG (0.48) | PPARGPPARACTSKPDE2A | |
| SCHEMBL26648342 | 0.82 | CTSS (0.48) | CTSSCTSKS1PR3MAPT | |
| SCHEMBL31750821 | 0.82 | S1PR3 (0.50) | PPARGPPARACTSSCTSKS1PR3 | |
| SCHEMBL15836874 | 0.82 | CTSK (0.64) | PPARGPPARACTSSCTSKS1PR3 | |
| SCHEMBL7050540 | 0.82 | CTSK (0.64) | PPARGPPARACTSSCTSKS1PR3 | |
| SCHEMBL14668300 | 0.82 | CTSK (0.64) | PPARGPPARACTSSCTSKS1PR3 | |
| SCHEMBL2837436 | 0.82 | JAK3 (0.42) | PPARGPPARACTSSCTSKPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-9815824-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | PPARG 220/4885PPARA 234/4885CTSS 2650/4885 |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRL1 | PPARG 675/4885PPARA 622/4885CTSS 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.